On August 4, Pediatrix Medical Group (NYSE:MD) reported second-quarter results that look strong on the surface. Adjusted earnings per share jumped to $0.63 from $0.53, and net revenue grew to $487.8 million. But look past the headline numbers, and the growth is coming largely from pricing and a shrinking share count, not from more patients walking through the door. That distinction matters for anyone trying to figure out how sustainable this quarter really was.
Pricing Power And Fewer Shares
Pediatrix’s headline numbers moved in the right direction across the board. Net revenue rose 4.0% year over year to $487.8 million, adjusted EBITDA climbed to $76.4 million from $73.2 million, and adjusted EPS jumped to $0.63 from $0.53 a year earlier. Over the first six months of 2026, adjusted EPS is up to $1.07 from $0.87, and adjusted EBITDA has grown to $134.6 million from $122.4 million.
The engine behind that growth is reimbursement, not visits. Same-unit revenue tied to net reimbursement factors rose 4.0% in the quarter, helped by improved cash collections, higher patient acuity in neonatology, and a shift toward commercial payors, whose share of services rose by 135 basis points. Recent acquisitions added another 2.1 percentage points of non-same-unit revenue growth.
Buybacks are doing real work on a per-share basis too. Pediatrix spent $42.7 million repurchasing shares in the quarter alone, helping cut weighted average diluted shares to 81.4 million from 85.5 million a year ago. The company carries $584 million in total debt against an untapped $450 million revolving line of credit, and it reaffirmed full-year Adjusted EBITDA guidance of $280 million to $300 million.
Fewer Patients, Rising Costs
The volume trends tell a different story. Hospital-based patient services fell 2.8% on a same-unit basis in the quarter, office-based services dropped 1.2%, and neonatal intensive care unit days declined 3.2%. Those are the core services Pediatrix bills for, and all three moved in the wrong direction even as total revenue grew.
Costs grew faster than the top line in some areas. Practice salaries and benefits expense rose to $336.1 million from $323.5 million, driven by higher clinical salaries and malpractice expense. General and administrative expenses climbed to $61.3 million from $55.7 million on executive transition costs and higher cash collection expense, and transformational and restructuring charges more than doubled to $8.5 million from $3.8 million as the company works through a revenue cycle management transition.
Cash on hand fell to $288.9 million at quarter-end from $375.2 million at the start of the year, and cash generated from continuing operations dipped to $126.3 million from $138.1 million a year earlier. GAAP diluted earnings per share, meanwhile, edged up to just $0.49 from $0.46, a far smaller gain than the jump in the adjusted number, a reminder of how much of this quarter’s improvement runs through non-GAAP adjustments and a lower share count rather than core operating results.
A Cheap Stock, Quiet Doubts
Hedge fund ownership of Pediatrix fell from 17 funds to 15 in the most recent quarter, a modest pullback in institutional interest. Short interest sits at 8.46% of the float, enough to suggest real skepticism but far from a crowded short. At the same time, the stock trades at a forward price-to-earnings ratio of just 8.21 as of September 15, a multiple that assumes little in the way of future growth. That combination points to a market that isn’t paying up for this quarter’s numbers.
What The Numbers Don’t Settle
Pediatrix delivered a quarter where nearly every headline metric improved, but the improvement leaned heavily on pricing, payor mix, and a shrinking share count rather than more patients being served. Continued reimbursement gains and disciplined buybacks could keep adjusted earnings climbing even if volumes stay soft, and the reaffirmed full-year guidance suggests management isn’t worried yet. But three straight quarters of falling same-unit volume, rising labor and administrative costs, and a shrinking cash balance raise the question of how long pricing alone can carry the business.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center